AbbVie and Genmab report that Epcoritamab R-CHOP reduced the risk of progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma, in the Phase 3 EPCORE DLBCL-2 trial. The combination remains investigational.
AbbVie has presented detailed Phase 1 data for ABBV-295 at EASD 2026, demonstrating meaningful body weight reduction, favorable tolerability and an approximately 11–12-day half-life. The investigational long-acting amylin analog is advancing toward Phase 2 development for chronic weight management, with potential dosing intervals extending beyond weekly administration.
AbbVie (NYSE: ABBV) has entered a new collaboration with life sciences AI platform Valkai to apply purpose-built AI across targeted areas of clinical research, aiming to generate insights faster and support shorter development timelines.
AbbVie JUVMO (tavapadon) has received FDA approval as the first selective D1/D5 receptor agonist for adults with Parkinson’s disease. AbbVie expects U.S. availability in October 2026.
AbbVie’s Phase 3 CERVINO trial shows etentamig, an investigational BCMA x CD3 bispecific, significantly improved response rate and progression-free survival versus standard therapies in relapsed/refractory multiple myeloma.
AbbVie’s Q2 2026 earnings show $16.99 billion in net revenues (+10.2%), record Skyrizi and Rinvoq growth, a $10.9 billion Apogee Therapeutics acquisition, and updated full-year adjusted EPS guidance.
AbbVie and Apogee Therapeutics have announced a definitive $10.9 billion acquisition agreement. The transaction enhances AbbVie’s global immunology portfolio by adding advanced assets like zumilokibart (APG777) for atopic dermatitis and APG273 for asthma.
Pharmaceutical titan AbbVie is in advanced discussions to purchase anti-inflammatory biotech developer Apogee Therapeutics for $10.9 billion in cash, marking its most significant bolt-on transaction since 2019.
AbbVie’s DECNUPAZ FDA approval provides a critical therapeutic lifeline for adult patients diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This ultra-rare and highly aggressive [Read More…]
AbbVie announced its first-quarter 2026 financial results, surpassing expectations with $15 billion in revenue and raising its full-year EPS guidance as next-generation immunology assets continue to offset Humira’s erosion.
